COVID-19

[Trends in Molecular Medicine] Scientists summarize what is known about the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and of acute COVID-19, and speculate that the pathogenesis of post-COVID-19 syndrome in some people may be similar to that of ME/CFS.

[Genetic Engineering & Biotechnology News] Researchers have been monitoring how COVID-19 vaccinations perform to determine whether booster shots will be needed, as variants of the novel coronavirus continue to mutate and spread. Now, the NIH announced they are beginning a Phase I/II clinical trial to test the safety and efficacy of different booster schedules.

[Stem Cells and Development] In this three-month follow-up study, researchers examined discharged patients who had received human umbilical cord-MSC therapy to assess the safety of this therapy and the health-related quality of life of these patients.

[Novartis Pharma AG (Globe Newswire, Inc.)] Novartis announced updated median overall survival (OS) results for Kisqali® in combination with fulvestrant in postmenopausal women with HR+/HER2- metastatic breast cancer. This combination demonstrated a clinically relevant OS benefit of more than a year compared with fulvestrant alone.

[Leukemia] The authors reported on 382 COVID-19 patients having undergone allogeneic or autologous hematopoietic cell transplantation reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH).

[Science Translational Medicine] Researchers reported evidence that the olfactory neuroepithelium was a major site of SARS-CoV2 infection with multiple cell types, including olfactory sensory neurons, support cells, and immune cells, becoming infected.